These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 19276246

  • 1. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 2. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 3. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 4. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
    Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.
    J Neurochem; 2007 Sep 15; 102(6):1749-1757. PubMed ID: 17696988
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov 15; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 15; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 8. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2013 Sep 15; 346(3):486-94. PubMed ID: 23843632
    [Abstract] [Full Text] [Related]

  • 9. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 15; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 10. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):164-73. PubMed ID: 22238213
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
    Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.
    Pharm Res; 2007 Sep 15; 24(9):1720-8. PubMed ID: 17380257
    [Abstract] [Full Text] [Related]

  • 12. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2011 May 15; 39(5):729-35. PubMed ID: 21282407
    [Abstract] [Full Text] [Related]

  • 13. Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.
    Sane R, Mittapalli RK, Elmquist WF.
    J Pharm Sci; 2013 Apr 15; 102(4):1343-54. PubMed ID: 23334925
    [Abstract] [Full Text] [Related]

  • 14. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 15; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 15. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2015 Dec 15; 102():200-7. PubMed ID: 26361725
    [Abstract] [Full Text] [Related]

  • 16. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.
    Drug Metab Dispos; 2010 Aug 15; 38(8):1371-80. PubMed ID: 20423956
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2020 Mar 15; 146(6):1631-1642. PubMed ID: 31304590
    [Abstract] [Full Text] [Related]

  • 18. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2019 Sep 03; 16(9):3842-3852. PubMed ID: 31329454
    [Abstract] [Full Text] [Related]

  • 19. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH.
    Cancer Res; 2005 Apr 01; 65(7):2577-82. PubMed ID: 15805252
    [Abstract] [Full Text] [Related]

  • 20. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
    Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Cancer Ther; 2010 Feb 01; 9(2):319-26. PubMed ID: 20103600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.